Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avanos Medical (AVNS) Research & Development (2016 - 2025)

Avanos Medical (AVNS) has disclosed Research & Development for 13 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 7.02% to $6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.3 million through Dec 2025, down 11.07% year-over-year, with the annual reading at $23.3 million for FY2025, 11.07% down from the prior year.
  • Research & Development hit $6.1 million in Q4 2025 for Avanos Medical, up from $6.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $8.4 million in Q3 2021 to a low of $5.4 million in Q1 2025.
  • Historically, Research & Development has averaged $6.8 million across 5 years, with a median of $6.9 million in 2023.
  • Biggest five-year swings in Research & Development: crashed 38.54% in 2021 and later rose 22.03% in 2022.
  • Year by year, Research & Development stood at $5.9 million in 2021, then increased by 22.03% to $7.2 million in 2022, then dropped by 5.56% to $6.8 million in 2023, then fell by 16.18% to $5.7 million in 2024, then rose by 7.02% to $6.1 million in 2025.
  • Business Quant data shows Research & Development for AVNS at $6.1 million in Q4 2025, $6.0 million in Q3 2025, and $5.8 million in Q2 2025.